SIVAS CUMHURIYET UNIVERSITESI

Their core work

Sivas Cumhuriyet University is a Turkish public university whose H2020 participation centers entirely on dangerous viral pathogens — specifically Crimean-Congo Haemorrhagic Fever (CCHF) and other viral haemorrhagic fevers (VHFs) such as Ebola. Their geographic location in central Anatolia is not accidental: Turkey is one of the highest-burden countries for CCHF in the world, giving the university direct access to endemic disease contexts, clinical cases, and field data that Western European partners cannot replicate. In H2020 projects, they contributed expertise in animal models and vaccine evaluation for CCHF, and later shifted toward rapid diagnostic technologies including lateral flow assays and point-of-care testing for multiple VHF pathogens. They operate as a specialist partner within large international consortia, providing endemic-region expertise and laboratory capacity rather than project leadership.

What they specialise in

How they've shifted over time

Cumhuriyet's H2020 participation began (2017) with upstream vaccine science — focusing on the pathogen itself, animal models, and preclinical evaluation of CCHF vaccines. By 2019, the focus moved downstream toward applied diagnostics: rapid detection at the bedside, multiplexed point-of-care platforms, and the practical challenge of identifying VHF cases in resource-limited settings. This shift from "develop a vaccine" to "detect the disease fast" reflects a broader turn in the global infectious disease community after Ebola outbreaks exposed the gap in field-deployable diagnostics. The twinning and capacity building keywords in the later project also suggest Cumhuriyet is positioning itself as a regional training hub, not just a research participant.

Cumhuriyet is moving from upstream pathogen research toward applied field diagnostics and regional capacity building, making them an increasingly practical partner for projects targeting low-resource or endemic-region deployment of infectious disease tools.

How they like to work

Cumhuriyet has participated in two projects without ever taking a coordinator role, positioning them consistently as a specialist contributor within larger multinational consortia. With 26 unique partners across only 2 projects, they have worked inside broad alliances — averaging 13 partners per project — which is typical for RIA health consortia tackling dangerous pathogens that require distributed geographic and laboratory expertise. There is no evidence of repeated partnership with the same institutions, suggesting they are valued for the specific endemic-region access they provide rather than as part of a fixed research network.

Despite only two projects, Cumhuriyet has accumulated 26 distinct consortium partners spanning 12 countries — an unusually wide network for an institution of this H2020 footprint, reflecting the inherently international nature of emerging infectious disease research. Their geographic reach extends well beyond Turkey into Western Europe, Africa, and likely Central Asia given the CCHF endemic zone.

What sets them apart

Cumhuriyet's key differentiator is geography: Sivas Province and the surrounding region of Turkey are among the highest-incidence areas for CCHF globally, giving this university access to real patient data, clinical expertise, and field conditions that no Western European institution can match. For any consortium working on CCHF vaccines, diagnostics, or outbreak response, Cumhuriyet provides an endemic-region anchor that satisfies both scientific and regulatory requirements for real-world validation. They are a rare bridge between European research infrastructure and a live-disease context that is otherwise inaccessible to most H2020 partners.

Highlights from their portfolio

• CCHFVaccine
  The largest and longest project in their portfolio (€140,250, running 2017–2025), focused on developing a vaccine for one of Europe's most dangerous tick-borne viruses — a disease where Turkey's endemic burden makes Cumhuriyet's participation scientifically essential.
• VHFMoDRAD
  This project extended Cumhuriyet's scope beyond CCHF to Ebola and multiple VHFs, demonstrating that their expertise is recognized as transferable across the entire class of haemorrhagic fever pathogens, not just the one endemic to their region.